Loading…
Trevi Therapeutics, Inc. is projected to rise to $19.30 by 2027, a +34% move from its current price of $14.45. TRVI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.10 | $14.46 | $14.83 | +0.06% |
| May 30 | $13.96 | $14.47 | $14.99 | +0.11% |
| May 31 | $13.86 | $14.47 | $15.12 | +0.17% |
| Jun 1 | $13.77 | $14.48 | $15.23 | +0.23% |
| Jun 2 | $13.70 | $14.49 | $15.33 | +0.28% |
| Jun 3 | $13.63 | $14.50 | $15.42 | +0.34% |
| Jun 4 | $13.58 | $14.51 | $15.50 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.58 | $14.51 | $15.50 | +0.40% |
| Week 2 | $13.26 | $14.57 | $16.00 | +0.80% |
| Week 3 | $13.03 | $14.62 | $16.41 | +1.20% |
| Week 4 | $12.86 | $14.68 | $16.77 | +1.60% |
| Week 5 | $12.71 | $14.74 | $17.10 | +2.01% |
| Week 6 | $12.58 | $14.80 | $17.41 | +2.41% |
| Week 7 | $12.46 | $14.86 | $17.71 | +2.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for chronic cough in IPF and non-IPF interstitial lung disease. It develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER and phase 2a in refractory chronic cough.
Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Trevi Therapeutics' stock TRVI trades at $14.13 per share and has a market capitalization of $2.01B. It is ranked 1998.
The price outlook reflected in the long-range forecast shows a bullish trajectory, with the 2026 average price at $14.13 and rising through 2030 to $31.78, then continuing higher to $125.94 by 2040 and $319.02 by 2050. The forecast also indicates substantial upside in max prices and rising ROIs, with max values reaching $46.08 in 2030, $211.14 by 2040, and $583.92 by 2050, and ROIs up to 124.9% in 2030 and 2157.8% by 2050.
Overall, the long-range outlook is bullish, suggesting meaningful upside potential over the coming years, though these figures are estimates rather than guarantees.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 6.6% above — a clean break opens room to run.
A major ceiling 14.3% above — clearing it would confirm fresh momentum.
Key TRVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.20 | Buy | $14.25 | Buy |
| MA 10 | $14.22 | Buy | $14.22 | Buy |
| MA 20 | $14.26 | Buy | $14.17 | Buy |
| MA 50 | $13.39 | Buy | $13.57 | Buy |
| MA 100 | $12.30 | Buy | $12.71 | Buy |
| MA 200 | $11.28 | Buy | $11.26 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.61 | Neutral |
| Stoch RSI (14) | 54.01 | Neutral |
| CCI (20) | 31.68 | Neutral |
| Williams %R (14) | -40.39 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -0.34 | Sell |
| Bollinger %B (20,2) | 0.59 | Neutral |
| Stochastic %K (14) | 59.61 | Neutral |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 53.68 | Neutral |
| Momentum (10) | -0.31 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 14.39 | Buy |
| ADX (14) | 15.23 | Neutral |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is BULLISH, reflecting constructive near-term momentum.
RSI(14) is 50, with the SMA50 at $13.25 and the SMA200 at $11.20. Near-term support is listed at $13.24 and resistance at $15.40, marking a defined range for the coming weeks.
The 30-day price range runs from $11.86 to $16.83, and the stock carries an annualized volatility of 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $14.45 | $21.68 | 0% | Neutral | |
| $15.43 | $19.30 | $25.51 | +34% | Bullish | |
| $19.02 | $24.39 | $33.33 | +69% | Bullish | |
| $21.71 | $28.43 | $39.87 | +97% | Bullish | |
| $24.67 | $32.89 | $47.17 | +128% | Bullish | |
| $33.42 | $45.31 | $66.28 | +214% | Bullish | |
| $38.57 | $53.10 | $79.05 | +268% | Bullish | |
| $41.81 | $58.42 | $88.37 | +304% | Bullish | |
| $45.75 | $64.81 | $99.50 | +349% | Bullish | |
| $47.58 | $68.30 | $106.30 | +373% | Bullish | |
| $83.85 | $127.80 | $210.73 | +784% | Bullish | |
| $193.17 | $326.10 | $585.21 | +21.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.99 | $14.45 | $16.96 | +0.00% |
| June 2026 | $12.43 | $14.57 | $17.46 | +0.81% |
| July 2026 | $12.88 | $15.22 | $18.47 | +4.47% |
| August 2026 | $13.46 | $16.00 | $19.61 | +5.13% |
| September 2026 | $13.52 | $16.15 | $19.94 | +0.93% |
| October 2026 | $13.57 | $16.29 | $20.26 | +0.87% |
| November 2026 | $14.03 | $16.90 | $21.15 | +3.76% |
| December 2026 | $14.24 | $17.22 | $21.68 | +1.92% |
Click any year to see its month-by-month TRVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TRVI is projected to trade between $9.99 and $21.68, averaging $14.45 — a potential gain of 0% from today's $14.45. Price action looks broadly range-bound.
Trevi Therapeutics, Inc.'s 2027 outlook centres on $19.30, within a $15.43 to $25.51 range. That is up +34% on the projected 2026 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, TRVI could reach as high as $33.33, with a base case around $24.39 and support toward $19.02 — roughly +69% from $14.45. Momentum favours further upside here.
Expect TRVI to range from $21.71 to $39.87 through 2029. The $28.43 average target implies a +97% move from current prices. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The TRVI price prediction for 2030 points to an average of $32.89 (low $24.67, high $47.17) — a potential gain of +128% on today's $14.45. Momentum favours further upside here.
In 2031, TRVI is projected to trade between $33.42 and $66.28, averaging $45.31 — a potential gain of +214% from today's $14.45. That is up +38% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Trevi Therapeutics, Inc.'s 2032 outlook centres on $53.10, within a $38.57 to $79.05 range. That is up +17% on the projected 2031 average. That marks a +268% change versus current levels. Momentum favours further upside here.
By 2033, TRVI could reach as high as $88.37, with a base case around $58.42 and support toward $41.81 — roughly +304% from $14.45. Buyers look set to stay in control over this stretch.
Expect TRVI to range from $45.75 to $99.50 through 2034. The $64.81 average target implies a +349% move from current prices. That is up +11% on the projected 2033 average. Momentum favours further upside here.
The TRVI price prediction for 2035 points to an average of $68.30 (low $47.58, high $106.30) — a potential gain of +373% on today's $14.45. Buyers look set to stay in control over this stretch.
In 2040, TRVI is projected to trade between $83.85 and $210.73, averaging $127.80 — a potential gain of +784% from today's $14.45. That is up +87% on the projected 2035 average. Momentum favours further upside here.
Trevi Therapeutics, Inc.'s 2050 outlook centres on $326.10, within a $193.17 to $585.21 range. That is up +155% on the projected 2040 average. That marks a +21.6x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRVI today (≈ 69.204152 TRVI) could be worth
$22,567.2
+$21,567.2 (+2157%) by 2050 · US Dollar
Based on the average projected TRVI price of $326.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRVIwould be worth at today's price.
$1,000 invested in TRVI on May 27, 2025 (≈ 162.337666 TRVI) would be worth
$2,345.78
+$1,345.78 (+134.6%) today · 2.35× · US Dollar
Based on a TRVI entry price of $6.16 vs. today's $14.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.88 | $1,041.07 | +4.1% |
| 1 month ago | $14.27 | $1,012.61 | +1.3% |
| 3 months ago | $11.52 | $1,254.34 | +25.4% |
| 6 months ago | $13.19 | $1,095.53 | +9.6% |
| 1 year ago | $6.16 | $2,345.78 | +134.6% |
| All time (5.0y) ago | $2.1 | $6,880.95 | +588.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRVI forecast.
Our base-case forecast reaches $29.00 around 2030.
Implied market cap at $29.00: $4.12B
In 2026, the average price is $14.13 with a min of $9.99 and a max of $21.39, and a 0% ROI, with a NEUTRAL sentiment. By 2027, the average rises to $18.92 (min $15.04, max $25.19) with a 33.9% ROI and a BULLISH sentiment. In 2028, the average is $24.06 (min $18.63, max $33.16) and ROI reaches 70.3%.
By 2030, the average is $31.78 (min $23.61, max $46.08) with a 124.9% ROI and a BULLISH sentiment.
The forecast continues to climb through 2031–2035, with 2031 avg $44.61 (ROI 215.7%), 2032 $52.14 (ROI 269%), 2033 $57.19 (ROI 304.7%), 2034 $63.76 (ROI 351.2%), and 2035 $66.28 (ROI 369.1%), all BULLISH.
In 2040, the average price is $125.94 (min $81.11, max $211.14) with a a remarkable ROI of 791.3% and a BULLISH sentiment. By 2050, the average price is $319.02 (min $183.99, max $583.92) with a ROI of 2157.8% and a BULLISH sentiment.
These figures illustrate a long-run, bullish trajectory with substantial upside potential, but they are estimates and not guarantees, reflecting uncertainty inherent in future market pricing.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg price of $31.78, with a min of $23.61 and a max of $46.08, and a ROI of 124.9%. The sentiment is BULLISH.
The long-range outlook is bullish, with ROIs rising from 33.9% in 2027 to 2157.8% by 2050; 2026 is Neutral with an average of $14.13 and 0% ROI.
Yes. The 2035 max price is $104.64, and the 2040 max price is $211.14, with the 2050 max price at $583.92.
Annualized volatility is 50%.
Current price is $14.13 and market cap is $2.01B.
Trevi Therapeutics, Inc. Community Discussion
0Share your Trevi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.